Users of the expensive Allergan PLC dry-eye drug Restasis may shed happy tears soon. San Diego-based ophthalmic pharmaceutical company Imprimis Pharmaceuticals Inc. announced it will make a cheaper, compounded version of the Allergan blockbuster.
Restasis, which pulled in $1.4 billion in U.S. sales last year, has been all over the news of late after Allergan tried to protect the Restasis franchise from patent review board scrutiny by transferring ownership of the patents to the St. Regis Mohawk. The patents were recently invalidated but Allergan is appealing.
Imprimis’ Oct. 19 announcement it would be entering the market with a cheaper, compounded version of the drug may provide patients with some price relief on the expensive treatment.
Imprimis said initial prescriptions for the compounded drug will be offered for 99 cents for a one-month supply and refills will be available at $79 per month. That compares with more than $5,000 per year for Restasis, according to Mark L. Baum, Imprimis’ chief executive officer.
Whether the market responds to this cheaper, alternative formulation of the dry-eye treatment is an open question, however, because compounded drugs require a doctor to write a prescription tailored specifically for the needs of a particular patient. The Imprimis product is made from Food and Drug Administration-approved drug components and compounded in FDA-inspected facilities, which are subject to specific manufacturing controls.
Approximately 30 million Americans may have dry-eye disease, which characterized by irritated, gritty, scratchy or burning eyes and blurred vision, Imprimis said.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)